Product DescriptionRabbit anti-SARS-CoV-2 envelope small membrane protein Polyclonal Antibody (Unconjugated), suitable for ELISA.
Application DetailsSARS-CoV Envelope antibody can be used for the detection of SARS-CoV Envelope protein in ELISA. It will detect 5 ng of free peptide at 1 μg/mL.
TargetSARS-CoV-2 envelope small membrane protein
Specificity Predicted reactivity based on immunogen sequence: SARS-CoV2 Envelope protein: (identity 82%, homology 91%)
Target Host SpeciesVirus
Immunogen DescriptionAnti-SARS-CoV Envelope antibody (R-1961-100) was raised against a peptide corresponding to 11 amino acids near the carboxy terminus of SARS-CoV Envelope protein.
The immunogen is located within the last 50 amino acids of SARS-CoV Envelope.
HomologyPredicted reactivity based on immunogen sequence: SARS-CoV2 Envelope protein: (identity 82%, homology 91%)
Isoform InformationSARS-CoV Envelope has one isoform (75aa).
Purity DescriptionAffinity-purified via peptide column.
FormatLiquid. SARS-CoV Envelope Antibody is supplied in PBS containing 0.02% sodium azide. Conc.1 mg/mL
Reconstitution InstructionsSpin vial briefly before opening.
Storage InstructionsSARS-CoV Envelope antibody can be stored at 2-8°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Batch NumberPlease see item label.
Expiration Date12 months after date of receipt (unopened vial).
Alternative NamesSARS-CoV Envelope Antibody: sM, 4, Envelope small membrane protein, E protein
NCBI Official Full NameEnvelope small membrane protein
NCBI Official SymbolE
NCBI OrganismSARS coronavirus
Scientific BackgroundSARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.
Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication.
Figure 1 ELISA Test
Antibodies: SARS-CoV Envelope Antibody, R-1961-100 (1 μg/mL). A direct ELISA was performed using immunogen as coating antigen and the anti-SARS-CoV Envelope antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 2 ng/mL to 1000 ng/mL.